3 results
Approved WMOPending
The aim is thereby to reduce the risk of serious infections and the need for regular CLL treatment.
Approved WMORecruiting
Primary objective• To evaluate efficacy of acalabrutinib/venetoclax (AV) in terms of undetectable minimal residual disease (uMRD) response in bone marrow (BM) after 26 cycles of treatment in patients with CLL previously treated with venetoclax and…
Approved WMORecruiting
The primary objective of this study is to investigate if an orthosis combined with exercise therapy results in less pain and less conversion to surgery than an orthosis alone in patients with CMC-1 OA at three months and one year after treatment…